Matricellular proteins and biomaterials

Matrix Biology

Volumn 37, Issue , 2014, Pages 183-191

  Morris, Aaron H ^a   Kyriakides, Themis R ^a,b,c  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Biocompatible; Biomaterials; Decellularization; Extracellular matrix; Foreign body response; Matricellular

Indexed keywords

BIOMIMETIC MATERIAL; CCN PROTEIN; MATRICELLULAR PROTEIN; OSTEONECTIN; OSTEOPONTIN; PROTEIN; TENASCIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; BIOMATERIAL; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; SCLEROPROTEIN; SPARC PROTEIN, HUMAN; THROMBOSPONDIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FOREIGN BODY; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; THICKNESS; TISSUE ENGINEERING; VASCULARIZATION; BIOLOGICAL MODEL; FOREIGN BODY REACTION; METABOLISM;

BIOCOMPATIBLE MATERIALS; CCN INTERCELLULAR SIGNALING PROTEINS; CELL ADHESION MOLECULES; EXTRACELLULAR MATRIX PROTEINS; FOREIGN-BODY REACTION; HUMANS; MODELS, BIOLOGICAL; OSTEONECTIN; OSTEOPONTIN; TENASCIN; THROMBOSPONDINS;

EID: 84908281707     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2014.03.002     Document Type: Review

References (125)

1. Adams J.C., Lawler J. The thrombospondins. Int. J. Biochem. Cell Biol. 2004, 36:961-968.
2. Agah A., Kyriakides T.R., Lawler J., Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol. 2002, 161:831-839.
3. Ahmed I., Liu H.-Y., Mamiya P.C., Ponery A.S., Babu A.N., Weik T., Schindler M., Meiners S. Three-dimensional nanofibrillar surfaces covalently modified with tenascin-C-derived peptides enhance neuronal growth in vitro. J. Biomed. Mater. Res. A 2005, 76:851-860.
4. Alford A.I., Hankenson K.D. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 2006, 38:749-757.
5. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20:86-100.
6. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2003, 22:63-71.
7. Badylak S.F. The extracellular matrix as a biologic scaffold material. Biomaterials 2007, 28:3587-3593.
8. Bär A., Dorfman S.E., Fischer P., Hilfiker-Kleiner D., Cebotari S., Tudorache I., Suprunov M., Haverich A., Hilfiker A. The pro-angiogenic factor CCN1 enhances the re-endothelialization of biological vascularized matrices in vitro. Cardiovasc. Res. 2010, 85:806-813.
9. Barker T.H., Baneyx G., Cardó-Vila M., Workman G.A., Weaver M., Menon P.M., Dedhar S., Rempel S.A., Arap W., Pasqualini R., Vogel V., Sage E.H. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 2005, 280:36483-36493.
10. Barker T.H., Framson P., Puolakkainen P.A., Reed M., Funk S.E., Sage E.H. Matricellular homologs in the foreign body response together diminish angiogenesis. Am. J. Pathol. 2005, 166:923-933.
11. Booth A.J., Hadley R., Cornett A.M., Dreffs A.A., Matthes S.A., Tsui J.L., Weiss K., Horowitz J.C., Fiore V.F., Barker T.H., Moore B.B., Martinez F.J., Niklason L.E., White E.S. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am. J. Respir. Crit. Care Med. 2012, 186:866-876.
12. Böer U., Spengler C., Jonigk D., Klingenberg M., Schrimpf C., Lu S., Harder M., Kreipe H., Haverich A., Wilhelmi M. Coating decellularized equine carotid arteries with CCN1 improves cellular repopulation, local biocompatibility, and immune response in sheep. Tissue Eng. Part A 2013, 19:1829-1842.
13. Bornstein P. Matricellular proteins: an overview. J. Cell Commun. Signal. 2009, 3:163-165.
14. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 2002, 14:608-616.
15. Bornstein P., Kyriakides T.R., Yang Z., Armstrong L.C., Birk D.E. Thrombospondin 2 modulates collagen fibrillogenesis and angiogenesis. J. Investig. Dermatol. Symp. Proc. 2000, 5:61-66.
16. Bornstein P., Agah A., Kyriakides T.R. The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. 2004, 36:1115-1125.
17. Boudriot U., Dersch R., Greiner A., WendorffJ.H. Electrospinning approaches toward scaffold engineering-a brief overview. Artif. Organs 2006, 30:785-792.
18. Bourget J., Gauvin R., Larouche D., Lavoie A., Labbé R., Auger F.A., Germain L. Human fibroblast-derived ECM as a scaffold for vascular tissue engineering. Biomaterials 2012, 33:9205-9213.
19. Bourgine P.E., Pippenger B.E., Todorov A., Tchang L., Martin I. Tissue decellularization by activation of programmed cell death. Biomaterials 2013, 34:6099-6108.
20. Bradshaw A.D. The role of SPARC in extracellular matrix assembly. J. Cell Commun. Signal. 2009, 3:239-246.
21. Bradshaw A.D., Puolakkainen P., Dasgupta J., Davidson J.M., Wight T.N., Helene Sage E. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J. Invest. Dermatol. 2003, 120:949-955.
22. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001, 19:816-827.
23. Brodbeck W.G., Patel J., Voskerician G., Christenson E., Shive M.S., Nakayama Y., Matsuda T., Ziats N.P., Anderson J.M. Biomaterial adherent macrophage apoptosis is increased by hydrophilic and anionic substrates in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10287-10292.
24. Bryers J.D., Giachelli C.M., Ratner B.D. Engineering biomaterials to integrate and heal: the biocompatibility paradigm shifts. Biotechnol. Bioeng. 2012, 109:1898-1911.
25. Calabro N.E., Kristofik N.J., Kyriakides T.R. Thrombospondin-2 and extracellular matrix assembly. Biochim. Biophys. Acta 2014, 1-7.
26. Cao W., Hench L.L. Bioactive materials. Ceram. Int. 1996, 8842:493-507.
27. Causa F., Netti P.A., Ambrosio L. A multi-functional scaffold for tissue regeneration: the need to engineer a tissue analogue. Biomaterials 2007, 28:5093-5099.
28. Chen C.-C., Lau L.F. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 2009, 41:771-783.
29. Chen H., Herndon M.E., Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000, 19:597-614.
30. Chen A.K., Delrio F.W., Peterson A.W., Chung K.-H., Bhadiraju K., Plant A.L. Cell spreading and proliferation in response to the composition and mechanics of engineered fibrillar extracellular matrices. Biotechnol. Bioeng. 2013, 110:2731-2741.
31. Chiquet-Ehrismann R. Molecules in focus: tenascins. Int. J. Biochem. Cell Biol. 2004, 36:986-990.
32. Crapo P.M., Gilbert T.W., Badylak S.F. An overview of tissue and whole organ decellularization processes. Biomaterials 2011, 32:3233-3243.
33. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998, 93:1159-1170.
34. Decup F., Six N., Palmier B., Buch D., Lasfargues J.J., Salih E., Goldberg M. Bone sialoprotein-induced reparative dentinogenesis in the pulp of rat's molar. Clin. Oral Investig. 2000, 4:110-119.
35. Dohan Ehrenfest D.M., de Peppo G.M., Doglioli P., Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009, 27:63-69.
36. Erickson H.P. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr. Opin. Cell Biol. 1993, 5:869-876.
37. Esch M.B., Post D.J., Shuler M.L., Stokol T. Characterization of in vitro endothelial linings grown within microfluidic channels. Tissue Eng. Part A 2011, 17:2965-2971.
38. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
39. Geetha M., Singh A.K., Asokamani R., Gogia A.K. Ti based biomaterials, the ultimate choice for orthopaedic implants - a review. Prog. Mater. Sci. 2009, 54:397-425.
40. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000, 19:615-622.
41. Gilbert T.W., Sellaro T.L., Badylak S.F. Decellularization of tissues and organs. J. Biomed. Mater. Res. A 2006, 27:3675-3683.
42. Goldberg M., Six N., Decup F., Buch D., Soheili Majd E., Lasfargues J.-J., Salih E., Stanislawski L. Application of bioactive molecules in pulp-capping situations. Adv. Dent. Res. 2001, 15:91-95.
43. Goldberg M., Lacerda-Pinheiro S., Priam F., Jegat N., Six N., Bonnefoix M., Septier D., Chaussain-Miller C., Veis A., Denbesten P., Poliard A. Matricellular molecules and odontoblast progenitors as tools for dentin repair and regeneration. Clin. Oral Investig. 2008, 12:109-112.
44. Goldberg M., Six N., Chaussain C., DenBesten P., Veis A., Poliard A. Dentin extracellular matrix molecules implanted into exposed pulps generate reparative dentin: a novel strategy in regenerative dentistry. J. Dent. Res. 2009, 88:396-399.
45. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8(3):171-179.
46. Hamilton D.W. Functional role of periostin in development and wound repair: implications for connective tissue disease. J. Cell Commun. Signal. 2008, 2:9-17.
47. Hartig S.M., Greene R.R., Dikov M.M., Prokop A., Davidson J.M. Multifunctional nanoparticulate polyelectrolyte complexes. Pharm. Res. 2007, 24:2353-2369.
48. Healy K.E., Thomas C.H., Rezania A., Kim J.E., McKeown P.J., Lom B., Hockberger P.E. Kinetics of bone cell organization and mineralization on materials with patterned surface chemistry. Biomaterials 1996, 17:195-208.
49. Hench L.L. Biomaterials: a forecast for the future. Biomaterials 1998, 19:1419-1423.
50. Heness G., Ben-Nissan B. Innovative bioceramics. Mater. Forum 2004, 27:104-114.
51. Hixson J.E., Shimmin L.C., Montasser M.E., Kim D.-K., Zhong Y., Ibarguen H., Follis J., Malcom G., Strong J., Howard T., Langefeld C., Liu Y., Rotter J.I., Johnson C., Herrington D. Common variants in the periostin gene influence development of atherosclerosis in young persons. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1661-1667.
52. Hsia H.C., Schwarzbauer J.E. Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 2005, 280:26641-26644.
53. Hunter G.K., Poitras M.S., Underhill T.M., Grynpas M.D., Goldberg H.A. Induction of collagen mineralization by a bone sialoprotein-decorin chimeric protein. J. Biomed. Mater. Res. 2001, 55:496-502.
54. Krady M.M., Zeng J., Yu J., MacLauchlan S., Skokos E.A., Tian W., Bornstein P., Sessa W.C., Kyriakides T.R. Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am. J. Pathol. 2008, 173:879-891.
55. Kudo Y., Hatano H., Ogawa I., Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol. Histopathol. 2007, 1:1167-1174.
56. Kühn B., del Monte F., Hajjar R.J., Chang Y.-S., Lebeche D., Arab S., Keating M.T. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat. Med. 2007, 13:962-969.
57. Kyriakides T.R., Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb. Haemost. 2003, 90:986-992.
58. Kyriakides T.R., Maclauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J. Cell Commun. Signal. 2009, 3:215-225.
59. Kyriakides T.R., Zhu Y.H., Smith L.T., Bain S.D., Yang Z., Lin M.T., Danielson K.G., Iozzo R.V., LaMarca M., McKinney C.E., Ginns E.I., Bornstein P. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 1998, 140:419-430.
60. Kyriakides T.R., Leach K.J., Hoffman A.S., Ratner B.D., Bornstein P. Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4449-4454.
61. Kyriakides T.R., Tam J.W.Y., Bornstein P. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J. Invest. Dermatol. 1999, 113:782-787.
62. Kyriakides T.R., Hartzel T., Huynh G., Bornstein P. Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. Mol. Ther. 2001, 3:842-849.
63. Kyriakides T.R., Cheung C.Y., Murthy N., Bornstein P., Stayton P.S., Hoffman A.S. pH-sensitive polymers that enhance intracellular drug delivery in vivo. J. Control. Release 2002, 78:295-303.
64. Kzhyshkowska J., Workman G., Cardó-Vila M., Arap W., Pasqualini R., Gratchev A., Krusell L., Goerdt S., Sage E.H. Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J. Immunol. 2006, 176:5825-5832.
65. Lan M.A., Gersbach C.A., Michael K.E., Keselowsky B.G., García A.J. Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries. Biomaterials 2005, 26:4523-4531.
66. Lawler J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 2000, 12:634-640.
67. Lawler J., Hynes R.O. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 1986, 103:1635-1648.
68. Leahy D.J., Hendrickson W.A., Aukhil I., Erickson H.P. Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. Science 1992, 258:987-991.
69. Levert H.S. Experiments on the use of metallic ligatures, as applied to arteries. Am. J. Med. Sci. 1829, 7:17-23.
70. Liao S., Ngiam M., Chan C.K., Ramakrishna S. Fabrication of nano-hydroxyapatite/collagen/osteonectin composites for bone graft applications. Biomed. Mater. 2009, 4:1-8.
71. Lindsley A., Snider P., Zhou H., Rogers R., Wang J., Olaopa M., Kruzynska-Frejtag A., Koushik S.V., Lilly B., Burch J.B.E., Firulli A.B., Conway S.J. Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer. Dev. Biol. 2007, 307:340-355.
72. Liu L., Chen G., Chao T., Ratner B.D., Sage E.H., Jiang S. Reduced foreign body reaction to implanted biomaterials by surface treatment with oriented osteopontin. J. Biomater. Sci. Polym. Ed. 2008, 19:821-835.
73. Liu S., Thompson K., Leask A. CCN2 expression by fibroblasts is not required for cutaneous tissue repair. Wound Repair Regen. 2014, 22:119-124.
74. Lorts A., Schwanekamp J.A., Elrod J.W., Sargent M.A., Molkentin J.D. Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. Circ. Res. 2009, 104:e1-e7.
75. Lv S., Bu T., Kayser J., Bausch A., Li H. Towards constructing extracellular matrix-mimetic hydrogels: an elastic hydrogel constructed from tandem modular proteins containing tenascin FnIII domains. Acta Biomater. 2013, 9:6481-6491.
76. Matsui Y., Morimoto J., Uede T. Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction. World J. Biol. Chem. 2010, 1:69-80.
77. McCall J.D., Lin C.-C., Anseth K.S. Affinity peptides protect transforming growth factor beta during encapsulation in poly(ethylene glycol) hydrogels. Biomacromolecules 2011, 12:1051-1057.
78. Mieszawska A.J., Kaplan D.L. Smart biomaterials - regulating cell behavior through signaling molecules. BMC Biol. 2010, 8:59.
79. Mitchell E.A., Chaffey B.T., McCaskie A.W., Lakey J.H., Birch M.A. Controlled spatial and conformational display of immobilised bone morphogenetic protein-2 and osteopontin signalling motifs regulates osteoblast adhesion and differentiation in vitro. BMC Biol. 2010, 8:57.
80. Mori R., Shaw T.J., Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J. Exp. Med. 2008, 205:43-51.
81. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J. Clin. Invest. 2001, 107:785-790.
82. Murphy-Ullrich J.E., Schultz-Cherry S., Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol. Biol. Cell 1992, 3:181-188.
83. Norris R.A., Moreno-Rodriguez R., Hoffman S., Markwald R.R. The many facets of the matricellular protein periostin during cardiac development, remodeling, and pathophysiology. J. Cell Commun. Signal. 2009, 3:275-286.
84. Norris R.A., Damon B., Mironov V., Kasyanov V., Moreno-rodriguez R., Trusk T., Potts J.D., Richard L., Davis J., Hoffman S., Wen X., Sugi Y., Kern C.B., Mjaatvedt C.H., Turner D.K., Oka T., Conway S.J., Molkentin J.D., Forgacs G., Markwald R.R., Carolina S. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J. Cell. Biochem. 2012, 101:695-711.
85. O'Toole G.C., Salih E., Gallagher C., FitzPatrick D., O'Higgins N., O'Rourke S.K. Bone sialoprotein-coated femoral implants are osteoinductive but mechanically compromised. J. Orthop. Res. 2004, 22:641-646.
86. Okamoto H., Imanaka-Yoshida K. Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc. Ther. 2012, 30:e198-e209.
87. Pallero M.A., Talbert Roden M., Chen Y.-F., Anderson P.G., Lemons J., Brott B.C., Murphy-Ullrich J.E. Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: implications for in-stent restenosis. J. Vasc. Res. 2010, 47:309-322.
88. Pan H., Jiang H., Chen W. The biodegradability of electrospun Dextran/PLGA scaffold in a fibroblast/macrophage co-culture. Biomaterials 2008, 29:1583-1592.
89. Patterson J., Hubbell J.A. SPARC-derived protease substrates to enhance the plasmin sensitivity of molecularly engineered PEG hydrogels. Biomaterials 2011, 32:1301-1310.
90. Perbal B. Rapid review CCN proteins: multifunctional signalling regulators. Lancet 2004, 363:62-64.
91. Petersen T.H., Calle E.A., Zhao L., Lee E.J., Gui L., Raredon M.B., Gavrilov K., Yi T., Zhuang Z.W., Breuer C., Herzog E., Niklason L.E. Tissue-engineered lungs for in vivo implantation. Science 2010, 329:538-541.
92. Polizzotti B.D., Arab S., Kühn B. Intrapericardial delivery of gelfoam enables the targeted delivery of Periostin peptide after myocardial infarction by inducing fibrin clot formation. PLoS One 2012, 7:1-11.
93. Puleo D.A., Nanci A. Understanding and controlling the bone-implant interface. Biomaterials 1999, 20:2311-2321.
94. Puolakkainen P., Bradshaw A.D., Kyriakides T.R., Reed M., Brekken R., Wight T., Bornstein P., Ratner B., Sage E.H. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am. J. Pathol. 2003, 162:627-635.
95. Puolakkainen P.A., Bradshaw A.D., Brekken R.A., Reed M.J., Kyriakides T., Funk S.E., Gooden M.D., Vernon R.B., Wight T.N., Bornstein P., Sage E.H. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J. Histochem. Cytochem. 2005, 53:571-581.
96. Ratner B.D. Replacing and renewing: synthetic materials, biomimetics, and tissue engineering in implant dentistry. J. Dent. Educ. 2001, 65:1340-1347.
97. Ratner B.D. Reducing capsular thickness and enhancing angiogenesis around implant drug release systems. J. Control. Release 2002, 78:211-218.
98. Ratner B.D., Bryant S.J. Biomaterials: where we have been and where we are going. Annu. Rev. Biomed. Eng. 2004, 6:41-75.
99. Ravi S., Haller C.A., Sallach R.E., Chaikof E.L. Cell behavior on a CCN1 functionalized elastin-mimetic protein polymer. Biomaterials 2012, 33:2431-2438.
100. Reinecke H., Robey T.E., Mignone J.L., Muskheli V., Bornstein P., Murry C.E. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc. Pathol. 2013, 22:91-95.
101. Reing J.E., Brown B.N., Daly K.A., Hsiong S., Huber A., Kullas K.E., Tottey S., Badylak S.F. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. Biomaterials 2010, 31:8626-8633.
102. Rezania A., Thomas C.H., Branger A.B., Waters C.M., Healy K.E. The detachment strength and morphology of bone cells contacting materials modified with a peptide sequence found within bone sialoprotein. J. Biomed. Mater. Res. 1997, 37:9-19.
103. Roach P., Eglin D., Rohde K., Perry C.C. Modern biomaterials: a review - bulk properties and implications of surface modifications. J. Mater. Sci. Mater. Med. 2007, 18:1263-1277.
104. Rodrigues M., Yates C.C., Nuschke A., Griffith L., Wells A. The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng. Part A 2013, 19:1972-1983.
105. Ruan K., Bao S., Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 2009, 66:2219-2230.
106. Saka O.M., Bozkir A. Formulation and in vitro characterization of PEGylated chitosan and polyethylene imine polymers with thrombospondin-I gene bearing pDNA. J. Biomed. Mater. Res. B Appl. Biomater. 2012, 100:984-992.
107. Sarvestani A.S., He X., Jabbari E. Osteonectin-derived peptide increases the modulus of a bone-mimetic nanocomposite. Eur. Biophys. J. 2008, 37:229-234.
108. Schultz G.S., Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 2009, 17:153-162.
109. Schultz-Cherry S., Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 1993, 122:923-932.
110. Seidman C.E., Seidman J.G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ. Res. 2011, 108:743-750.
111. Shin H., Jo S., Mikos A.G. Biomimetic materials for tissue engineering. Biomaterials 2003, 24:4353-4364.
112. Shubina A.N., Egorova A.A., Baranov V.S., Kiselev A.V. Recent advances in gene therapy of endometriosis. Recent Pat. DNA Gene Seq. 2013, 7:1-10.
113. Song J.J., Ott H.C. Organ engineering based on decellularized matrix scaffolds. Trends Mol. Med. 2011, 17:424-432.
114. Stevens M.M., George J.H. Exploring and engineering the cell surface interface. Science 2005, 310:1135-1138.
115. Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., Detmar M. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:14888-14893.
116. Streit M., Stephen A.E., Hawighorst T., Matsuda K., Lange-asschenfeldt B., Brown L.F., Vacanti J.P., Detmar M. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy 2002, 2004-2012.
117. Sullivan M.M., Sage E.H. Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int. J. Biochem. Cell Biol. 2004, 36:991-996.
118. Sweetwyne M.T., Pallero M.A., Lu A., Van Duyn Graham L., Murphy-Ullrich J.E. The calreticulin-binding sequence of thrombospondin 1 regulates collagen expression and organization during tissue remodeling. Am. J. Pathol. 2010, 177:1710-1724.
119. Tsai A.T., Rice J., Scatena M., Liaw L., Ratner B.D., Giachelli C.M. The role of osteopontin in foreign body giant cell formation. Biomaterials 2005, 26:5835-5843.
120. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27:103-118.
121. Wei H., Wu S., Feng Z., Zhou W., Dong Y., Wu G., Bai S., Zhao Y. Increased fibroblast functionality on CNN2-loaded titania nanotubes. Int. J. Nanomedicine 2012, 7:1091-1100.
122. Xia Z., Triffitt J.T. A review on macrophage responses to biomaterials. Biomed. Mater. 2006, 1:R1-R9.
123. Xu L., Anderson A.L., Lu Q., Wang J. Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation. Biomaterials 2007, 28:750-761.
124. Yang Z., Strickland D.K., Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 2001, 276:8403-8408.
125. Yuan Y., Altalhi W.A., Ng J.J., Courtman D.W. Derivation of human peripheral blood derived endothelial progenitor cells and the role of osteopontin surface modification and eNOS transfection. Biomaterials 2013, 34:7292-7301.